CompanyHealth
Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
2023Founded
BostonHQ
$20,000,000Series A
oncologybiotechnologybtx-a51ck1-alpha-inhibitorcdk7-inhibitorcdk9-inhibitor